{
    "nct_id": "NCT06163430",
    "official_title": "A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia",
    "inclusion_criteria": "* Male or female participants ≥ 18 years of age at the time of signing the informed consent\n* Have an ECOG performance status score of 0 to 2\n* Have an established cytopathologically confirmed diagnosis of BCR-ABL1 positive CML in Chronic Phase\n* Have received treatment with active site targeting TKIs and have treatment failure, suboptimal response, or treatment intolerance\n* Prior treatment with asciminib may be allowed\n* Adequate organ function, as assessed by local laboratory\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Systemic antineoplastic therapy (including prior TKIs, interferon-alfa, therapeutic antibodies, chemotherapy) or other experimental therapy 7 days before the first dose of TERN-701\n* Have completed previous anticancer therapy without resolution of all associated clinically significant toxicity (to ≤ Grade 2 or baseline)",
    "miscellaneous_criteria": "Key"
}